|   | 
Author (up) Adeberg, S.; Harrabi, S.B.; Bougatf, N.; Bernhardt, D.; Mohr, A.; Rieber, J.; Koelsche, C.; Rieken, S.; Debus, J.
Title Do Increased Doses to Stem-Cell Niches during Radiation Therapy Improve Glioblastoma Survival? Type Journal Article
Year 2016 Publication Stem Cells International Abbreviated Journal Stem Cells Int
Volume 2016 Issue Pages 8793462
Abstract Background and Purpose. The reasons for the inevitable glioblastoma recurrence are yet understood. However, recent data suggest that tumor cancer stem cells (CSCs) in the stem-cell niches, with self-renewing capacities, might be responsible for tumor initiation, propagation, and recurrence. We aimed to analyze the effect of higher radiation doses to the stem-cell niches on progression-free survival (PFS) and overall survival (OS) in glioblastoma patients. Materials and Methods. Sixty-five patients with primary glioblastoma treated with radiation therapy were included in this retrospective analysis. The SVZ and DG were segmented on treatment planning magnetic resonance imaging, and the dose distributions to the structures were calculated. The relationship of dosimetry data and survival was evaluated using the Cox regression analysis. Results. Conventionally fractionated patients (n = 54) who received higher doses (D mean >/= 40 Gy) to the IL SVZ showed improved PFS (8.5 versus 5.2 months; p = 0.013). Furthermore, higher doses (D mean >/= 30 Gy) to the CL SVZ were associated with increased PFS (10.1 versus 6.9 months; p = 0.025). Conclusion. Moderate higher IL SVZ doses (>/=40 Gy) and CL SVZ doses (>/=30 Gy) are associated with improved PFS. Higher doses to the DG, the second stem-cell niche, did not influence the survival. Targeting the potential cancer stem cells in the SVZ might be a promising treatment approach for glioblastoma and should be addressed in a prospective randomized trial.
Address Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany; Heidelberg Ion-Beam Therapy Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany; Heidelberg Institute of Radiation Oncology (HIRO), University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
Corporate Author Thesis
Publisher Place of Publication Editor
Language English Summary Language Original Title
Series Editor Series Title Abbreviated Series Title
Series Volume Series Issue Edition
ISSN 1687-966X ISBN Medium
Area Expedition Conference
Notes PMID:27429623 Approved no
Call Number ref @ user @ Serial 96645
Permanent link to this record